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Abstract
Background: Epigenetic changes during ageing and their relationship with cancer are under the focus of intense
research. RASSF1A and NORE1A are novel genes acting in concert in the proapoptotic pathway of the RAS
signalling. While NORE1A has not been previously investigated in the human liver, recent reports have suggested
that RASSF1A is frequently epigenetically methylated not only in HCC but also in the cirrhotic liver.
Methods: To address whether epigenetic changes take place in connection to age and/or to the underlying
disease, we investigated RASSF1A and NORE1A gene promoter methylation by conventional methylation specific
PCR and Real-Time MSP in a series of hepatitic and non-hepatitic livers harboring regenerative/hyperplastic
(cirrhosis/focal nodular hyperplasia), dysplastic (large regenerative, low and high grade dysplastic nodules) and
neoplastic (hepatocellular adenoma and carcinoma) growths.
Results: In the hepatitic liver (chronic hepatitic/cirrhosis, hepatocellular nodules and HCC) we found widespread
RASSF1A gene promoter methylation with a methylation index that increased from regenerative conditions
(cirrhosis) to hepatocellular nodules (p < 0.01) to HCC (p < 0.001). In the non-hepatitic liver a consistent pattern
of gene methylation was also found in both lesional (focal nodular hyperplasia and hepatocellular adenoma) and
non-lesional tissue. Specifically, hepatocellular adenomas (HA) showed a methylation index significantly higher
than that detected in focal nodular hyperplasia (FNH) (p < 0.01) and in non-lesional tissue (p < 0.001). In non-
lesional liver also the methylation index gradually increased by ageing (p = 0.002), suggesting a progressive
spreading of methylated cells over time. As opposed to RASSF1A gene promoter methylation, NORE1A gene was
never found epigenetically alterated in both hepatitic and non-hepatitic liver.
Conclusion: We have shown that in non-lesional, regenerative and neoplastic liver the RASSF1A gene is
increasingly methylated, that this condition takes place as an age-related phenomenon and that the early setting
and spreading over time of an epigenetically methylated hepatocyte subpopulation, might be related to liver
tumorigenesis.
Published: 10 April 2006
BMC Cancer 2006, 6:89 doi:10.1186/1471-2407-6-89
Received: 05 August 2005
Accepted: 10 April 2006
This article is available from: http://www.biomedcentral.com/1471-2407/6/89
© 2006 Di Gioia et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 12
(page number not for citation purposes)
BMC Cancer 2006, 6:89 http://www.biomedcentral.com/1471-2407/6/89Background
A new family of tumor suppressor genes encoding RAS-
binding proteins and named RASSF1 has been recently
discovered [1,2]. They are located within a critical region
at 3p21.3 and have two main splicing isoforms RASSF1A
and 1C. The expression of the longer isoform, RASSF1A, is
lost in many tumor lines and primary tumors by promoter
methylation, while RASSF1C remains unmethylated [2-
11]. It has been suggested that RASSF1A methylation is
one of the most common aberration so far identified in
human cancers and that the loss of the functional protein
may promote the development of many human tumors
[12]. Methylation of RASSF1A promoter has been docu-
mented in 85% [13], 100% [14], 95% [15], 93% [16] and
67% [17] of hepatocellular carcinomas (HCC). Interest-
ingly, non neoplastic hepatitic/cirrhotic tissue usually
adjacent to HCC, beside other methylated genes [18,19],
frequently shows RASSF1A gene methylation ranging
from 70% [13,15] to 82.75% [14], while non-neoplastic
liver, or far from tumors, is not methylated [13,15,17].
These results suggest that RASSF1A methylation might be
a potential marker of incipient malignancy in the human
hepatocarcinogenesis.
In an autopsy series, Waki et al recently reported [20], that
RASSF1A gene promoter is largely methylated in the
human liver and that this epigenetic change may be
related to age.
Given that age-related methylation is a process that affect
non-lesional cells and precedes tumor formation [21], the
early setting of a hepatocyte subpopulation with RASSF1A
methylation, might be a potential and long-lasting for
oncogenic injuries.
We designed a study aimed to ascertain the frequency of
RASSF1A methylation in non-lesional, cirrhotic, hyper-
plastic, dysplastic and neoplastic liver. Moreover we per-
formed a quantification study, by Real-Time PCR, to
document whether the gene is methylated in relation to
age and/or to the underlying disease. Given that the func-
tional proapoptotic role of RASSF1A as tumor suppressor,
has been recently associated to the homologue gene
NORE1A [22-24] we also evaluated the methylation status
of the latter gene in the same non-lesional and patholog-
ical conditions.
Methods
Tissue samples and DNA extraction
Consecutive cases from 38 hepatitic/cirrhotic patients
with and without hepatocellular carcinoma (HCC) and/
or hepatocellular nodules (HN), from 13 patients with
focal nodular hyperplasia (FNH) or hepatocellular ade-
noma (HA) and 5 human cell lines (hepatoma cell lines:
Plc/Prf/5, Huh6, Huh7 and HepG2, and Chang, a normal
hepatocyte cell line) were collected for study. Patient's
characteristics (age, sex, etiology of hepatitis, type of
lesions) are reported in Table 1. The series included 26
HCCs, 17 high-grade dysplastic nodules (HGDN), 28 non
high-grade dysplastic nodules (large regenerative/low-
grade dysplastic nodules), 5 hepatocellular adenomas
(HA) and 8 focal nodular hyperplasias (FNH). The study
was conducted in accordance with the guidelines of the
Ethics Committee and Internal Scientific Board of our
institution (Istituto Clinico Humanitas, Rozzano, Milan,
Italy).
After identification of the different lesions on the hema-
toxylin-eosin stained slides, individual lesions were care-
fully microdissected from 20-µm-thick paraffin sections.
In all cases hepatocytes represented the main cellular pop-
ulation (≥ 80% of overall cellularity). In selected cases
(Table 1) of FNH and HA, different samples were taken
from the same lesional and non-lesional liver in order to
assess individual inter-sample methylation pattern and
levels heterogeneity. The non-lesional liver samples were
taken far from the lesions.
Collected materials were dewaxed by washing in xylene,
and rinsed in ethanol. The dried tissues were digested
using proteinase K and subjected to classical DNA extrac-
tion using phenol/chloroform/isoamylalcohol and etha-
nol precipitation. After precipitation, DNA was
resuspended in water and quantified by spectrophotomet-
ric analysis (260 nm).
RASSF1A and NORE1A methylation-specific PCR (MSP)
Sodium bisulfite modification
We designed a set of primers targeted to amplify a 111
base pair sequence located in the upstream region of the
RASSF1A promoter (ranging from -135 to -24 base pairs
from the starting site of exon 1) (Table 2). This sequence
was selected because it showed the highest CpG island
density of the whole promoter.
Methylation-specific PCR was carried-out as previously
reported [18,25]. Genomic DNA was modified by treat-
ment with sodium bisulfite, which converts all unmethyl-
ated cytosines to uracil, then to thymidine during the
subsequent PCR step. One µg of DNA in a volume of 50
µl were denatured by adding sodiumhydroxide to a final
concentration of 0.2 M and incubating for 10 min at
37°C. Thirty µl of 10 mM hydroquinone and 520 µl of 3
M sodium bisulfite (pH 5.0), both freshly prepared, were
added to the denatured DNA. The sample was mixed gen-
tly, overlaid with enough mineral oil to cover the surface
of the aqueous phase, and incubated at 55°C for 16–20 h.
Under this conditions, complete selective conversion of
unmethylated cytosine to uracil can be achieved [26]. The
modified DNA was desalted through Wizard DNA Clean-Page 2 of 12
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Table 1: Clinico-pathological features of the series. Numbers in columns refer to the number of individual lesions and to the number of 
tissue samples (parenthesis).
Pts No Age Sex Etiology HCC n = 26 
(30)
HN n = 45 
(45)
HA n = 5 
(13)
FNH n = 8 
(22)
Cirrhosis n = 
37 (39)
NLL n = 13 
(34)
Hepatitic Livers
1 70 M HBV 1 (1) -- -- -- 1 (1) --
2 48 M HBV 1 (1) 2 (2) -- -- 1 (1) --
3 50 M HBV -- 2 (2) -- -- 1 (1) --
4 41 M HBV -- 1 (1) -- -- 1 (1) --
5 41 M HBV -- 3 (3) -- -- 1 (1) --
6 59 M HCV -- 2 (2) -- -- 1 (1) --
7 56 M HCV -- 1 (1) -- -- 1 (1) --
8 58 M HCV -- 1 (1) -- -- 1 (1) --
9 75 F HCV 1 (4) 3 (3) -- -- 1 (1) --
10 42 M HCV 1 (1) 2 (2) -- -- 1 (1) --
11 59 F HCV 1 (2) 1 (1) -- -- 1 (1) --
12 71 F HCV 1 (1) 2 (2) -- -- 1 (1) --
13 71 F HCV 1 (1) 3 (3) -- -- 1 (2) --
14 57 M HCV 1 (1) -- -- -- 1 (1) --
15 62 F HCV 1 (1) -- -- -- 1 (1) --
16 67 M HCV 1 (1) -- -- -- 1 (1) --
17 74 M HCV 1 (1) -- -- -- 1 (1) --
18 67 M HCV 1 (1) -- -- -- 1 (1) --
19 70 F HCV 1 (1) -- -- -- 1 (1) --
20 69 M HCV 1 (1) -- -- -- 1 (1) --
21 68 F HCV 1 (1) -- -- -- 1 (1) --
22 54 M HBV/HCV -- 2 (2) -- -- 1 (1) --
23 49 M HBV/HDV 1 (1) 1 (1) -- -- 1 (1) --
24 53 M HBV/HDV -- 3 (3) -- -- 1 (1) --
25 52 F HBV/HDV -- 4 (4) -- -- 1 (1) --
26 62 M HBV/HDV/HCV 1 (1) 5 (5) -- -- -- --
27 65 M Cryptogenic 1 (1) -- -- -- 1 (1) --
28 48 F Cryptogenic 1 (1) -- -- -- 1 (1) --
29 72 M Cryptogenic 1 (1) -- -- -- 1 (1) --
30 57 M Cryptogenic -- 2 (2) -- -- 1 (1) --
31 51 F Cryptogenic 1 (1) -- -- -- 1 (1) --
32 73 M Cryptogenic 1 (1) -- -- -- 1 (1) --
33 70 F Cryptogenic 1 (1) -- -- -- 1 (1) --
34 49 M Cryptogenic -- 3 (3) -- -- 1 (2) --
35 69 M Cryptogenic 1 (1) 1 (1) -- -- 1 (1) --
36 22 F Wilson desease -- 1 (1) -- -- 1 (1) --
37 65 M Alcholic 1 (1) -- -- -- 1 (1) --
38 70 M Haemocromato
sis
1 (1) -- -- -- 1 (1) --
Non-Hepatitic Livers
39 28 M -- -- -- -- 1 (3) -- 1 (4)
40 30 F -- -- -- -- 1 (1) -- 1 (1)
41 39 M -- -- -- -- 1 (4) -- 1 (4)
42 47 F -- -- -- -- 1 (3) -- 1 (4)
43 26 F -- -- -- -- 1 (1) -- 1 (1)
44 33 M -- -- -- -- 1 (5) -- 1 (4)
45 54 M -- -- -- -- 1 (4) -- 1 (4)
46 33 F -- -- -- -- 1 (1) -- 1 (1)
47 44 F -- -- -- 1 (4) -- -- 1 (3)
48 36 F -- -- -- 1 (1) -- -- 1 (1)
49 34 F -- -- -- 1 (3) -- -- 1 (2)
50 38 F -- -- -- 1 (4)* -- -- 1 (4)
51 40 F -- -- -- 1 (1) -- -- 1 (1)
HCC = hepatocellular carcinoma; HN = hepatocellular nodules; HA = hepatocellular adenoma; FNH = focal nodular hyperplasia; NLL = non-
lesional liver.
* Multiple adenomatosis.
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water. Desulphonation was carried-out adding 5.5 µl of
NaOH 3 M and incubating DNA for 5 min at room tem-
perature. Modified DNA was precipited with sodium ace-
tated 3 M, ethanol and 1 µl of glycogen as carrier; finally
was resuspended in 50 µl of distillated water and DNA
concentration was measured by spectrophotometric anal-
ysis. The DNA was stored at -20°C until use.
The methylation status of RASSF1A and NORE1A was
determined by the MSP method of Herman et al. with the
following modifications, previously described [26]. Five
microliters of modified DNA were amplified in a stage I
PCR with a primer set that recognise the bisulfite-modi-
fied template but do not discriminate between methylated
and unmethylated alleles (Table 2). Three microliters of
the stage I PCR product were subjected to a stage II PCR in
which primers specific to methylated or unmethylated
template were used. DyNAzyme polymerase (Finnzymes)
and 0.4 µmol/l of each primer in a 30 µl final volume
were used in all PCRs. The PCR protocol for stage I was as
follows: 94°C for 4 min, then denature at 94°C for 30 sec,
anneal at 48°C for 30 sec for RASSF1A and 52°C for 30
sec for NORE1A, extension at 72°C for 30 sec for 20
cycles, followed by a 10 min of final extension. Primer
sequences used in a stage II amplifications are detailed in
Table 2. Annealing temperature for RASSF1A was 55°C to
amplify methylated and unmethylated sequences, for a
total of 25 cycles and annealing temperature for NORE1A
was 58°C to amplify methylated and unmethylated
sequences, for a total of 25 cycles. This nested PCRs are
able to detect 1 methylated allele in 50,000 unmethylated
alleles [26]. All PCRs were performed with positive meth-
ylation control, a human placental DNA treated in vitro
with excess of SssI methyltransferase that generates a com-
pletely methylated DNA. Ten microliters of PCR products
were run on a 2% agarose gel and visualized by staining
with ethidium bromide.
To evaluate the prevalence of methylation at CpG islands
in the context of the sequence, MSP PCR products from all
cell lines and from 5 randomly selected samples/each
lesion cathegory (total n = 35) were subjected to direct
cycle sequencing, using Big Dye Terminator Cycle
Sequencing Kit chemistry (ABI PRISM Big Dye Terminator
Cycle Sequencing Kit; PE Applied Biosystems, War-
rington, United Kingdom) and were run on ABI PRISM
310 Genetic Analyzer (PE Applied Biosystems, Foster City,
CA, USA).
Real-Time MSP
Real-Time Methylation Specific PCR (MSP) was used for
the quantification of the methylated and unmethylated
RASSF1A promoters in all samples under study. Reactions
were in triplicate for each individual sample.
Real-time PCR is based on the continuous optical moni-
toring of a fluorogenic PCR [27]. PCR amplifications were
performed using DyNAmo HS SyBR Green qPCR Kit
(Finnzymes) according to the manufacturer's instructions.
SYBR Green I is specific for double-stranded DNA and flu-
oresces when bound to the amplified double-stranded
PCR product, thereby enabling direct quantification of
amplified DNA without labeled probes [28].
Amplifications were carried out in 96-well plates in an
Chromo 4 thermalcycler (MJ Research Inc.), with 0.2 µM
primers specific to methylated or unmethylated bisulfite-
modified template and 50 ng of modified DNA in a 20 µl
final reaction volume. The primers used for RASSF1A real-
time MSP were the same used for conventional MSP
(Table 2). Thermal cycling was initiated with a incubation
step of 15 min at 95°C, followed by 45 cycles (95°C for
15 sec, 55°C for 20 sec, 72°C for 20 sec) with a single flu-
orescent reading taken at the end of each cycle. Each run
was completed with a melting curve analysis to confirm
the specificity of amplification and lack of primer dimers.
Threshold cycle values, Ct, were determined by the
Opticon2 software. A calibration curve was run in parallel
with each analysis. Human cell lines, LoVo and HeLa, pre-
viously shown to be respectively RASSF1A emimethylated
and unmethylated by conventional MSP, were used for
constructing the calibration curve for the RASSF1A M and
U real-time MSP (correlation coefficient were: r = 0.992 ±
0,007 for M and r = 0,997 ± 0,003 for U). To set-up the cal-
ibration curve, we prepared serial dilutions of LoVo and
Table 2: Primers used in this study
Primer Forward Reverse
RASSF1A mod GGGTTTTATAGTTTTTGTATTTAGGTT AACTCAATAAACTCAAACTCCCC
RASSF1A met CGGTTTTTTTTAGTTTTTTTTCGTCG TAACTTTAAACGCTAACAAACGCGAA
RASSF1A unmet TGTGTGGTTTTTTTTAGTTTTTTTTTGTTG CCCAACATAACCCAATTAAACCCA
NORE1A mod GAATTTTGTAGTTGTTTTAGGTGAAGA CTACTCCCR*AACCAACCCC
NORE1A met TATTCGCGTAGACGTCGTTTGGTAC AAACCGCAACCTACTAAACGAAACG
NORE1A unmet ATTTATATTTGTGTAGATGTTGTTTGGTA
TGGA
TTTAAAAAAACCACAACCTACTAAACAA
AACA
*R = G or APage 4 of 12
(page number not for citation purposes)
BMC Cancer 2006, 6:89 http://www.biomedcentral.com/1471-2407/6/89HeLa DNA, containing 10, 100, 500, 1000, 2500 and
5000 genome-equivalents, one genome-equivalent being
the amount of a particular target sequence in a single ref-
erence cell (Figure 1). A conversion factor of 6.6 pg of
DNA per diploid cell was used for expressing quantitative
results in genome equivalents [29,30].
The methylation index (%) in a sample was calculated
according to the following equation:
where M and U are genome-equivalents of methylated
and unmethylated RASSF1A sequences obtained by the
interpolation of Ct values with M and U calibration
curves.
A representative set of the original graphs (n = 12) from
each group of lesions occurring in both hepatitic and non
hepatitic liver is reported [see Additional file 1 and 2].
Statistical analysis
Differences in the degree of methylation among categories
of lesions were analyzed by linear mixed models (random
effect model) accounting for the within subject correla-
tions. Statistical association between age and methylation
index were analyzed by Pearson correlation. p < 0.05 was
considered to be statistically significant. Statistical analy-
sis were performed by using STATA 9 software.
Results
RASSF1A promoter methylation in hepatitic liver
Qualitative analysis for the presence of methylated alleles by MSP
RASSF1A promoter methylation was detected by conven-
tional MSP, in 100% (26/26) HCC, 86.6% (39/45) HN
and 81.1% (30/37) cirrhotic livers. Figure 2 (upper panel)
shows the methylation pattern of conventional MSP in
cases of HCC and paired cirrhosis. HCC cell lines, but not
the cell line Chang, were also methylated. DNA sequenc-
ing indicates that for methylated alleles, all (5/5; 100%)
CpG sites in the context of the analyzed sequence (Figure
2) were resistant to bisulfite conversion, whereas all cyto-
sine at non-CpG (17/17, 100%) sites were converted to
thymidine residues (Figure 2). Conversely unmethylated
samples never showed any resistant-to-bisulphite-conver-
sion CpG site. No correlation was found between
Methylation index
M
M U
=
+
×100
RASSF1A calibration curve of methylated DNA (LoVo): plot of Ct against the input target quantity (common logarithmic scale)Figure 1
RASSF1A calibration curve of methylated DNA (LoVo): plot of Ct against the input target quantity (common logarithmic scale). 
The input target quantity is expressed as genome equivalents of LoVo DNA. The correlation cofficient is 0.995.Page 5 of 12
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Upper panel: RASSF1A promoter region with CpG islands subjected to analysis; underlined is the sequence reported in the mid-dle panel showing the methylation pr file of RASSF1A detected by MSP i  HCC and corresponding cirrhosisFigure 2
Upper panel: RASSF1A promoter region with CpG islands subjected to analysis; underlined is the sequence reported in the mid-
dle panel showing the methylation profile of RASSF1A detected by MSP in HCC and corresponding cirrhosis. Middle panel: 
Methylation profile of RASSF1A detected by MSP in HCC and corresponding cirrhosis of cases 14,16,18 and 37. DNASssI 
treated: positive control for methylation; M: molecular marker; Human Placental DNA: negative control for methylation; m: 
methylated; u: unmethylated. The illustrated sequence refers to a HCC (case n = 37) showing both methylated and unmethyl-
ated alleles. Lower panel: Methylation profile of NORE1A detected by MSP in HCC and corresponding cirrhosis of cases 
14,16,18 and 37. DNASssI treated: positive control for methylation; M: molecular marker; Human Placental DNA: negative 
control for methylation; m: methylated; u: unmethylated. The illustrated sequence refers to a HCC (case n = 37) showing the 
exclusive presence of unmethylated alleles.
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Quantitative evaluation of RASSF1A methylation by Real-Time MSPFigure 3
Quantitative evaluation of RASSF1A methylation by Real-Time MSP. The median value of methylation index, 25 and 75% percen-
tiles, and minimum ad maximum values detected in liver cirrhosis, hepatocellular nodules (HN) and hepatocellular carcinoma 
(HCC) is reported in panel A; the median value of methylation index, 25 and 75% percentiles, and minimum and maximum val-
ues detected in non-lesional liver (NLL), focal nodular hyperplasia (FNH) and hepatocellular adenoma (HA) is reported in panel 
B.
BMC Cancer 2006, 6:89 http://www.biomedcentral.com/1471-2407/6/89RASSF1A gene promoter methylation with the etiology of
cirrhosis.
Quantitative analysis for the prevalence of methylated alleles by Real 
Time MSP
The calculated methylation indices for cell lines were as
follows: HepG2 99.53%, Plc/Prf/5 100%, Huh7 100%,
Huh6 100%, Chang 0.12%.
A gradual but significant increase in the methylation
index of RASSF1A was seen from cirrhosis to HN to HCC
(Figure 3A). Cirrhotic tissue had a methylation index
lower than that detected in HN (p < 0.01) and the latter a
methylation index significantly lower than that detected
in HCC (p < 0.001). HN were grouped together because
no statistical difference was seen as to the methylation
index among LGDN, HGDN and LRN (data not shown).
No correlation was found between RASSF1A methylation
index with the etiology of cirrhosis.
RASSF1A promoter methylation in non-hepatitic liver
Qualitative analysis for the presence of methylated alleles by MSP
RASSF1A promoter methylation was detected by conven-
tional MSP, in 100% (5/5) HA, 87.5% (7/8) FNH and
84.6% (11/13) non-lesional liver.
Quantitative analysis for the prevalence of methylated alleles by Real 
Time MSP
Hepatocellular adenomas (HA) showed a methylation
index significantly higher than that detected in focal nod-
ular hyperplasia (FNH) (p < 0.01) and in non-lesional tis-
sue (p < 0.001) (Figure 3B). As shown in Table 3 a certain
degree of inter-sample heterogeneity was seen in methyl-
ation index in individual cases of non-lesional liver, FNH
and HA with multiple sampling. Specifically, a methyla-
tion index < 10% was detectable in 7/13 cases (15/34
samples) of non-lesional liver, 2/8 cases (4/22 samples)
of FNH but never in HA. By contrast a methylation index
> 50% was seen in 2/13 cases (2/34 samples) of non-
lesional liver, 2/8 cases (3/22 samples) of FNH and 3/5
cases (7/13 samples) of HA.
Table 3: RASSF1A methylation index in hepatocellular adenoma (HA), focal nodular hyperplasia (FNH) and corresponding non-lesional 
liver (NLL) with viable multiple samplings. Each dot refers to RASSF1A methylation index (%) in one sampling. In brackets: number of 
tissue samples analyzed in each group of lesions.
Patien
t
Age HA (n = 13) FNH (n = 22) NLL (n = 34)
43 26
39 28 ❍ ❍ ❍ ❍
40 30 ❍
46 33
44 33 ❍ ❍ ❍ ❍
49 34 ● ● ❍ ❍
48 36 ❍
50 38
41 39 ❍ ❍ ❍ ❍ ❍ ❍
51 40 ● ●
47 44 ● ● ● ● ❍
42 47 ●
45 54 ● ● ●
❍ = RASSF1A methylation index: <10%
 = RASSF1A methylation index: 10–50%
●  = RASSF1A methylation index: >50%Page 8 of 12
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methylation index by ageing (p = 0.002) (Figure 4).
NORE1A gene promoter methylation in hepatitic and non-
hepatitic liver
In all samples under study NORE1A gene was always
found unmethylated by conventional MSP (Figure 2;
lower panel).
Discussion
We investigated the methylation profile of RASSF1A and
NORE1A promoter genes, in non-lesional, cirrhotic,
hyperplastic, dysplastic and neoplastic (benign and
malignant) hepatocellular growths. These two genes are
functionally thought to act in concert to mediate proap-
optotic signal on the RAS pathway in vivo [31]. Given that
RAS gene is not alterated in human hepatocarcinogenesis,
we sought to analyze by MSP if these RAS effectors are epi-
genetically altered by promoter methylation in the above
conditions. In keeping with several authors [13-16] we
observed high frequency of RASSF1A methylation in HCC
(100%) and associated cirrhosis (81.1%). In addition we
observed a high RASSF1A methylation frequency (86.6%)
in hepatocellular dysplastic nodules.
Interestingly, the RASSF1A methylation rate in cirrhosis
(81–82%) and corresponding HCC (98–100%), as
detected by MSP (qualitative assay), occured with a sur-
prisingly overlapping frequency in 3 different geographic
regions: Italy (mediterranean area, present work), North
Europe [32] and China [14]. Given the different etiology
of chronic liver disease in these regions, the above results
might suggest that the very high rate of RASSF1A methyl-
ation in the cirrhosis-HCC sequence is a peculiar early
molecular feature of hepatocarcinogenesis in the cirrhotic
setting, unrelated to a specific etiology.
Lee et al. [17] reported 67% promoter methylation in
HCC, 10% in dysplastic nodules and no methylation in
non neoplastic hepatitic/cirrhotic liver. This discrepancy
Non-lesional liver: methylation index of RASSF1A according to ageFigur  4
Non-lesional liver: methylation index of RASSF1A according to age.Page 9 of 12
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MSP), relying on the analysis of a different set of CpGs.
Indeed Lee et al. [17] designed a set of primers targeted to
amplify a sequence of exon 1 of the gene and not of its
promoter, as we did.
Opposite results to RASSF1A, were obtained by analyzing
NORE1A promoter methylation, which was not investi-
gated previously in the human liver. This gene, which is
supposed to act in concert with RASSF1A as proapoptotic
mediator of RAS signalling, was never found methylated
in our series of non-lesional, cirrhotic, hyperplastic, dys-
plastic and neoplastic liver. Hesson et al. [24] reported
that this gene was variably methylated in a number of dif-
ferent human tumors such as breast, pulmonary, kidney
and colorectal. In the present study, the unmethylation of
NORE1A in the liver might be related to opposite epige-
netic alteration of RASSF1A. According to this hypothesis
Hesson et al. [33] recently reported frequent RASSF1A,
but not NORE1A, methylation in gliomas. Given that
both genes act in concert, it can be speculated that the
methylation of NORE1A could result biologically redun-
dant.
Based on these results we performed a RASSF1A quantita-
tive analysis of methylation by Real-Time PCR on non-
lesional, cirrhotic, hyperplastic, neoplastic liver and for
the first time on dysplastic hepatocellular nodules.
In hepatitic livers, our quantitative analysis showed that
HCC, as compared to cirrhosis, had a significantly higher
methylation index of RASSF1A. This result is in keeping
with that of Zhong et al. [15] measuring the number of
methylated hepatocytes in HCC and cirrhosis by PCR-
RFLP. Interestingly, in our series, quantitation of RASSF1A
methylation showed that hepatocellular nodules had a
methylation index in between cirrhosis and HCC, in keep-
ing with their putative HCC precursor role.
The methylation of RASSF1A gene promoter, already set
in our cases of cirrhosis, also supports a tumor-independ-
ent mechanism of gene methylation. Waki et al [20]
recently showed, in an autopsy study, that all patients over
40 yrs had the RASSF1A gene promoter methylated in the
liver, suggesting an age-related mechanism of gene meth-
ylation.
To probe whether RASSF1A gene promoter was also meth-
ylated in connection to age we included in our series, non-
lesional liver samples taken far from lesion in patients
with FNH or HA.
In the non-lesional liver, one or more samples of 5 out of
9 patients under 40 yrs, showed a methylation index
grater than 10%. Interestingly, methylation index in non-
lesional liver showed a gradual increase with ageing, that
started before 30 years [32]. These results suggest that age-
related methylation of RASSF1A gene promoter takes
place early in a small subpopulation of cells of the human
liver and that this fraction of hepatocytes is fated to
increase by ageing. This observation resembles that
reported by Nakagawa et al. [34] as to the methylation
pattern of hMLH1 in the human colon, where methylated
cells are distributed at multiple sites in the colon and
methylation increased with age. Conceivably the fraction
of hepatocytes already methylated with age at the
RASSF1A gene promoter, might become, over time, more
susceptible to oncogenic injuries. Because our results were
obtained in a limited number of cases, the gradual
increase of RASSF1A methylation index by age should be
confirmed in larger series including younger subjects such
as children and fetuses. As detected between HCC (a neo-
plastic growth) and cirrhosis (a regenerative growth), we
also observed a statistically significant increase in the
methylation index between hepatocellular adenoma (a
neoplastic growth) and focal nodular hyperplasia (a
hyperplastic growth). It has been suggested by Toyota et
al. [21] that age-related methylation by potentially affect-
ing genes that regulate both cell growth and differentia-
tion could account in part for the hyperproliferative state
that precedes tumor formation, thus linking age-related
methylation to cancer-related methylation. The analysis
of RASSF1A methylation index in the whole series of cases
showed a gradual increase in the methylation index from
non-lesional liver to regenerative/hyperplastic conditions
(chronic liver disease and FNH), to preneoplastic lesions
(HN) to overt tumors (HA and HCC). This result suggests
that quantitative analysis of RASSF1A gene promoter
methylation, rather than the detection of methylation
bands "per se", might be clinically relevant. Quantitative
results should also be compared to expression data (not
available in the present series given the lack of specific
antibodies and the unavailability of frozen material for
mRNA analysis), to document the functional role of
methylation.
Conclusion
In conclusion we have shown that in non-lesional, cir-
rhotic, hyperplastic, dysplastic and neoplastic liver
growths the RASSF1A gene is methylated, that this condi-
tion takes place as an age-related phenomenon and that
the early setting and spreading over time of an epigeneti-
cally alterated hepatocyte subpopulation, might be
related to liver tumorigenesis.
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